Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 15/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.44 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.42 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.42 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.42 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27833947 | 0.84 | MTOR (0.51) | MTORPIK3CAPIK3R1 | |
| SCHEMBL24756512 | 0.81 | MTOR (0.52) | MTORPIK3C3PIK3CAPIK3R1RICTOR | |
| SCHEMBL30933171 | 0.81 | MTOR (0.52) | MTORPIK3C3PIK3CAPIK3R1RICTOR | |
| SCHEMBL20605988 | 0.81 | MTOR (0.46) | MTORPIK3CAPIK3R1RICTORRPTOR | |
| SCHEMBL28267155 | 0.81 | MTOR (0.43) | MTORPIK3C3PIK3CAPIK3R1RICTOR | |
| SCHEMBL20605987 | 0.81 | MTOR (0.46) | MTORPIK3CAPIK3R1RICTORRPTOR | |
| SCHEMBL20606347 | 0.81 | MTOR (0.46) | MTORPIK3CAPIK3R1RICTORRPTOR | |
| SCHEMBL30356496 | 0.80 | MTOR (0.54) | MTORPIK3CAPIK3R1RICTORRPTOR | |
| SCHEMBL26151682 | 0.79 | MTOR (0.47) | MTORPIK3CAPIK3R1RICTORRPTOR | |
| SCHEMBL29947221 | 0.78 | PIK3CA (0.50) | MTORPIK3C3PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-05-04 | — | — | US | disclosed |
| US-9174963-B2 | Triazine compounds as PI3 kinase and MTOR inhibitors | PFIZER INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150011752-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2015-01-08 | — | — | US | disclosed |
| US-8859542-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140248239-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8748421-B2 | Triazine compounds as P13 kinase and MTOR inhibitors | WYETH LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130315865-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8575159-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8445486-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130109670-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2013-01-03 | — | — | US | disclosed |
| US-8217036-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2012-07-10 | — | — | US | disclosed |
| US-8039469-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | MTOR 1/4885PIK3C3 15/4885PIK3CA 2/4885 |
| US-20130109670-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3C3 26/4885PIK3CA 3/4885 |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3C3 26/4885PIK3CA 3/4885 |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3C3 26/4885PIK3CA 3/4885 |
| US-20150011752-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3C3 26/4885PIK3CA 3/4885 |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3C3 26/4885PIK3CA 3/4885 |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | MTOR 1/4885PIK3C3 15/4885PIK3CA 2/4885 |
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3C3 26/4885PIK3CA 3/4885 |
| US-20140248239-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3C3 26/4885PIK3CA 3/4885 |
| US-20130315865-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3C3 26/4885PIK3CA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.